{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:06:43Z","timestamp":1783933603402,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24793","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:08:54Z","timestamp":1705666134000},"page":"e24793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-1573","authenticated-orcid":false,"given":"Abhenil","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-6618","authenticated-orcid":false,"given":"Faris","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolacion","family":"Molto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-525X","authenticated-orcid":false,"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.heliyon.2024.e24793_bib1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after Stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24793_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-015-0634-8","article-title":"Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence","volume":"17","author":"Santini","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"10001","key":"10.1016\/j.heliyon.2024.e24793_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24793_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e24793_bib5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e24793_bib6","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24793_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24793_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24793_bib9","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1038\/s41598-022-09949-5","article-title":"A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time","volume":"12","author":"Wilson","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24793_bib10","first-page":"787","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J. Clin. Orthod."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24793_bib11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24793_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-021-06147-1","article-title":"Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey","volume":"187","author":"McGee","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e24793_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100402","article-title":"Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: challenges and lessons learnt from comparison of the UK and Australian experience","volume":"31","author":"Porter","year":"2021","journal-title":"J Bone Oncol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24793_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000499931","article-title":"St. Gallen\/vienna 2019: a brief summary of the Consensus discussion on the optimal primary breast cancer treatment","volume":"14","author":"Balic","year":"2019","journal-title":"Breast Care"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e24793_bib15","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.21.00311","article-title":"Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer (BOOG 2006-04): randomized phase III TEAM-IIB trial","volume":"40","author":"Vliek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24793_bib16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e24793_bib17","first-page":"2062","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care Ontario and American society of clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J. Clin. Orthod."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24793_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jrsm.1211","article-title":"Neither fixed nor random: weighted least squares meta-regression","volume":"8","author":"Stanley","year":"2017","journal-title":"Res. Synth. Methods"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24793_bib19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0895-4356(90)90093-5","article-title":"Indexes and boundaries for \u201cquantitative significance\u201d in statistical decisions","volume":"43","author":"Burnand","year":"1990","journal-title":"J. Clin. Epidemiol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24793_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","article-title":"Prognosis of patients with early breast cancer receiving 5 Years vs 2 Years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial","volume":"7","author":"Friedl","year":"2021","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24793_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djz215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24793_bib22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24793_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24793_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24793_bib25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24793_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24793_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24793_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24793_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24793_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2012.210","article-title":"Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II\/III breast cancer","volume":"107","author":"Aft","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"28","key":"10.1016\/j.heliyon.2024.e24793_bib31","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24793_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.05.015","article-title":"Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36\/ABCSG 29)","volume":"64","author":"von Minckwitz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e24793_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e24793_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2021.02.034","article-title":"Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: a secondary analysis of MA.27, MA.17 and MA.17R","volume":"149","author":"Ethier","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e24793_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24793_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(18)30750-2","article-title":"Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis","volume":"20","author":"Saad","year":"2019","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24793_bib37","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24793_bib38","doi-asserted-by":"crossref","first-page":"pkab054","DOI":"10.1093\/jncics\/pkab054","article-title":"MAF amplification and adjuvant clodronate outcomes in early-stage breast cancer in NSABP B-34 and potential impact on clinical practice","volume":"5","author":"Paterson","year":"2021","journal-title":"JNCI Cancer Spectr."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24793_bib39","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3390\/cancers14081898","article-title":"Definition of high-risk early hormone-positive HER2-negative breast cancer: a Consensus review","volume":"14","author":"Garutti","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24793_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-021-00286-w","article-title":"Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer","volume":"7","author":"Puglisi","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24793_bib41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024008247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024008247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:23:10Z","timestamp":1783930990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024008247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024008247"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24793","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24793"}}